"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

While AMD’s first Zen 5 CPUs disappointed everyone in gaming, the latest X3D versions have more than made up for that. The ...

The RX 9070 XT GPU, if it’s real, was likely given out to AMD’s brand partners prior to the launch of the RX 9070 XT/non-XT. Whoever got their hands on this card ended up keeping it and selling it, ...

Shares in Advanced Micro Devices (AMD) climbed today despite China throwing down another technological gauntlet to the U.S. with a new $11 ...

Something to look forward to: AMD has confirmed the pricing and launch date for its latest high-performance processors, the Ryzen 9 9950X3D and Ryzen 9 9900X3D, with MSRPs of $699 and $599 ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Oracle ...

A machine-learning UV absorbance spectroscopy method enables rapid, label-free detection of microbial contamination in cell therapy product manufacturing.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...